Beyond diabetes and obesity: GLP-1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation.
This review examines the potential neuroprotective role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) — a drug class established for managing type 2 diabetes and obesity — in the context of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. The authors propose that neurodegeneration is driven by a self-reinforcing cycle of chronic neuroinflammation and central metabolic dysfunction, worsened by impaired insulin/IGF-1 signalling, mitochondrial dysfunction, and pro-inflammatory microglial activation triggered by misfolded protein aggregates. The review synthesizes preclinical and clinical trial data to argue that GLP-1RAs may disrupt this cycle via a dual mechanism: reducing central insulin resistance and directly suppressing neuroinflammatory cascades by modulating glial responses, inhibiting pro-inflammatory cytokines, and reducing oxidative stress in the CNS. The authors conclude that GLP-1RAs represent a promising, translatable therapeutic strategy for neurodegeneration and call for large-scale human trials. Limitations include the review's reliance on synthesizing heterogeneous preclinical and early clinical data, without original data collection, and the mechanistic conclusions remain to be validated in robust, adequately powered human studies.
Why this grade: This is a narrative review synthesizing preclinical and early clinical trial data without original data collection, so it cannot itself be graded as direct human evidence despite referencing clinical studies.
Neurodegenerative diseases, including debilitating conditions like Alzheimer's and Parkinson's, are characterized by progressive neuronal loss, a process fundamentally driven by persistent chronic neuroinflammation and central metabolic dysfunction. In these disorders, persistent danger signals, such as the aggregation of misfolded proteins, activate resident microglial cells, leading to a functional shift toward a detrimental, pro-inflammatory phenotype. This damaging cycle is critically exacerbated by impaired Insulin/Insulin-like Growth Factor 1 signalling, which compromises neuronal mitochondrial homeostasis, decreases energy production, and severely diminishes synaptic plasticity, thereby establishing a self-perpetuating cycle of metabolic disturbance and neuroinflammation. This review examines the burgeoning therapeutic potential of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs), a class of drugs traditionally used to manage type 2 diabetes mellitus and obesity, as neuroprotective agents. We discuss mechanistic insights demonstrating how GLP-1RAs operate through a crucial dual action: effectively mitigating central insulin resistance and directly suppressing the multi-faceted neuroinflammatory cascade. By activating specific neuronal and glial signalling pathways, GLP-1RAs are shown to restore mitochondrial function, increase neuronal resilience, and crucially, modulate adverse glial cell responses-inhibiting the release of major pro-inflammatory cytokines and significantly reducing cellular oxidative stress within the central nervous system. Clinical trials and comprehensive preclinical data, analysed through diverse experimental models of neurodegeneration, strongly support the translational potential relevance of these compounds. The accumulating evidence suggests that GLP-1RAs offer a promising, readily available therapeutic strategy to disrupt the core inflammatory and metabolic pathways common across many neurodegenerative conditions, warranting further investigation in large-scale human trials.
Educational summary of published research — not medical advice. License: cc by. Full text is shown only where licensing permits.